FindMyKOL
Clinical trialNCT06197672RecruitingPhase 1Interventional

Chimeric Antigen Receptor T Cell Redirected to Target CD4 Positive Relapsed Refractory Acute Myeloid Leukemia (AML ) as a Bridge to Allogeneic Stem Cell Transplant

SponsorHuda SalmanEnrollment30Acute Myeloid Leukemia
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This study is designed as a single arm open label traditional Phase I, 3+3, study of CD4-redirected chimeric antigen receptor engineered T-cells (CD4CAR) in subjects with relapsed or refractory AML. The study will evaluate safety in this subject population and also the presence of efficacy signal described by elimination of residual disease to qualify subjects for stem cell transplant.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • University of Miami Sylvester Comprehensive Cancer Center

    Miami, Florida, United States

    Amer Beitinjaneh, MD
    Recruiting
  • Indiana University Melvin and Bren Simon Comprehensive Cancer Center

    Indianapolis, Indiana, United States

    Recruiting
  • Riley Hospital for Children

    Indianapolis, Indiana, United States

    Jodi Skiles, MD
    Recruiting
  • the University of Texas Md Anderson Cancer Center

    Houston, Texas, United States

    Nicholas Short, MD
    Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

CD4CAR
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
19 Mar 2024
Primary completion
31 Dec 2027
Completion
31 Dec 2042
Last update posted
24 Jun 2026
Registered enrollment
30
Registry id
NCT06197672
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.